Evidence map›Paper›PMID 28577178›Full record

Trial reportEuropean journal of drug metabolism and pharmacokinetics2018

Population Pharmacokinetic Analysis of Bisoprolol in Patients with Stable Coronary Artery Disease.

Valentina N Nikolic, Slobodan M Jankovic, Marina Deljanin-Ilic, Sanja S Stojanovic, Miroslav Lj Nikolic, Slavoljub Zivanovic, Dragana Stokanovic, Tatjana Jevtovic-Stoimenov, Jasmina R Milovanovic

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of drug metabolism and pharmacokinetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Valentina N NikolicDepartment of Pharmacology and Toxicology, Faculty of Medicine, University of Nis, Medicinski fakultet, Katedra za farmakologiju sa toksikologijom, Bulevar dr Zorana Djindjica 81, 18000, Nis, Serbia. valentina@medfak.ni.ac.rs.
Slobodan M JankovicDepartment of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Marina Deljanin-IlicDepartment of Cardiology, Faculty of Medicine, University of Nis, Bulevar dr Zorana Djindjica 81, Nis, Serbia.
Sanja S StojanovicInstitute of Treatment and Rehabilitation, Faculty of Medicine, University of Nis, Srpskih junaka 2, Niska Banja, Serbia.
Miroslav Lj NikolicInstitute of Treatment and Rehabilitation, Faculty of Medicine, University of Nis, Srpskih junaka 2, Niska Banja, Serbia.
Slavoljub ZivanovicLaboratory for Functional Genomics and Proteomics, Research Center for Biomedicine, Faculty of Medicine, University of Nis, Bulevar dr Zorana Djindjica 81, Nis, Serbia.
Dragana StokanovicDepartment of Pharmacology and Toxicology, Faculty of Medicine, University of Nis, Medicinski fakultet, Katedra za farmakologiju sa toksikologijom, Bulevar dr Zorana Djindjica 81, 18000, Nis, Serbia.
Tatjana Jevtovic-StoimenovLaboratory for Functional Genomics and Proteomics, Research Center for Biomedicine, Faculty of Medicine, University of Nis, Bulevar dr Zorana Djindjica 81, Nis, Serbia.
Jasmina R MilovanovicDepartment of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesBisoprolol is a selective beta adrenergic antagonist commonly used in treatment of coronary artery disease (CAD). The aim of our analysis was to estimate and identify different factors that could affect bisoprolol clearance (CL) and develop a population pharmacokinetic model in patients with stable coronary artery disease (CAD).

methodsPopulation pharmacokinetic analysis was performed by using sixty-six plasma concentrations from the same number of patients (mean age 60.26 ± 9.68 years; mean total body weight 80.37 ± 12.93 kg) with CAD. We examined the effects of various clinical and demographic parameters using nonlinear mixed-effect modeling (NONMEM) with ADVAN1 with TRANS2 subroutine. The pharmacokinetics of bisoprolol in patients with CAD were suitably defined by an oral one-compartment model.

resultsThe typical mean value for bisoprolol CL, estimated by the base model, in the target population was 6.76 l/h. The only demographic covariate which affected bisoprolol pharmacokinetic variability was creatinine clearance (CLcr). The final model of bisoprolol clearance was described by following equation: CL (l/h) = 2.83 + 0.0385 × CLcr (ml/min). Validation of the final model was performed in a group of 17 patients using the validation set and bootstrapping analysis.

conclusionsThese findings suggest that one of the causes of clearance of bisoprolol variability in patients with CAD is the difference in renal function.

Indexed as

Adrenergic beta-AntagonistsAdultAgedBisoprololCoronary Artery DiseaseFemaleHumansMaleMiddle AgedNonlinear DynamicsAdrenergic beta-AntagonistsBisoprolol

Identifiers

PMID28577178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.